FWD1802

DRUG3 trials

Sponsors

Forward Pharmaceuticals Co., Ltd.

Conditions

Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IVER+ Breast CancerER+/HER2- Breast CancerHealthyLocally Advanced Breast CancerLocally Advanced Breast Cancer (LABC)

Phase 1

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

RecruitingNCT06064812

Forward Pharmaceuticals Co., Ltd.Breast Cancer Stage IV, ER+/HER2- Breast Cancer, Locally Advanced Breast Cancer +1

Start: 2023-09-12End: 2028-03-01Target: 99Updated: 2026-02-10

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

RecruitingNCT07002177

Forward Pharmaceuticals Co., Ltd.Breast Cancer Stage I, Breast Cancer Stage II, ER+ Breast Cancer +2

Start: 2025-06-01End: 2028-11-01Target: 196Updated: 2026-01-07

Evaluation of the Food Effecton the Pharmacokinetics of FWD1802 in Healthy Subjects

Not yet recruitingNCT07476963

Forward Pharmaceuticals Co., Ltd.Healthy

Start: 2026-03-01End: 2026-08-01Target: 18Updated: 2026-03-17

Related Papers

A phase 1 FIH study of novel oral SERD FWD1802 in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer with or without ESR1 mutations.

Journal of Clinical Oncology2025-05-28